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In GN4 rat liver epithelial cells, angiotensin II (Ang
II) produces intracellular calcium and protein kinase
C (PKC) signals and stimulates ERK and JNK activity.
JNK activation appears to be mediated by a calcium-
dependent tyrosine kinase (CADTK). To define the
ERK pathway, we established GN4 cells expressing an
inhibitory Ras(N17). Induction of Ras(N17) blocked
EGF- but not Ang II- or phorbol ester (TPA)-dependent
ERK activation. In control cells, Ang II and TPA
produced minimal increases in Ras–GTP level and Raf
kinase activity. PKC depletion by chronic TPA exposure
abolished TPA-dependent ERK activation but failed to
diminish the effect of Ang II. In PKC-depleted cells,
Ang II increased Ras–GTP level and activated Raf and
ERK in a Ras-dependent manner. In PKC depleted
cells, Ang II stimulated Shc and Cbl tyrosine phos-
phorylation, suggesting that without PKC, Ang II
activates another tyrosine kinase. PKC-depletion did
not alter Ang II-dependent tyrosine phosphorylation
or activity of p125FAK , CADTK, Fyn or Src, but PKC
depletion or incubation with GF109203X resulted in
Ang II-dependent EGF receptor tyrosine phosphoryl-
ation. In PKC-depleted cells, EGF receptor-specific
tyrosine kinase inhibitors blocked Ang II-dependent
EGF receptor and Cbl tyrosine phosphorylation, and
ERK activation. In summary, Ang II can activate
ERK via two pathways; the latent EGF receptor, Ras-
dependent pathway is equipotent to the Ras-independ-
ent pathway, but is masked by PKC action. The
prominence of this G-protein coupled receptor to EGF
receptor pathway may vary between cell types




Multiple extracellular stimuli activate extracellular signal
regulated protein kinases (ERK) including growth factors,
phorbol esters and peptide hormones that activate
G-protein coupled receptors (GPCRs). The mechanisms
of activation by various stimuli may differ in part to
control the strength and duration of the ERK response,
which is involved in diverse cellular functions such as
cell growth and differentiation. The growth factor receptor
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pathway is the best characterized (Marshall, 1995). For
example, epidermal growth factor (EGF) triggers EGF
receptor tyrosine autophosphorylation, resulting in a
phosphotyrosine-dependent association of Shc and/or Grb2
with the receptor. Membrane translocation of the Grb2–
SOS complex stimulates Ras-GDP to -GTP exchange, in
turn stimulating Raf, MEK and ERK in series. More
recently, alternative pathways involving other docking
proteins and guanine nucleotide exchange factors have
been studied. One major EGF receptor tyrosine phos-
phorylated, 120 kDa substrate, Cbl, has been implicated
in Ras activation pathways in some cell types and can
serve as a sensitive marker for EGF-dependent adaptor
protein tyrosine phosphorylation (Fukazawaet al., 1995;
Galisteoet al., 1995; Meisner and Czech, 1995; Tanaka
et al., 1995; Budayet al., 1996; Panchamoorthyet al.,
1996; Reedquistet al., 1996; Ribonet al., 1996).
Another class of ERK activators, the protein kinase C
(PKC) family of protein Ser/Thr kinases, are stimulated
by the tumor promoter, TPA, or physiologically through
activation of phospholipases C and D, which liberate
diacylglycerol and inisotol triphosphate (IP3) or diacylgly-
cerol alone, respectively. PKC stimulation activates ERK
through several pathways depending on the cell type
(Cobb and Goldsmith, 1995). The mechanisms, both Ras-
dependent and independent, are not well understood.
Specifically, the Ras-independent mechanisms by which
PKC activates ERK, bypassing Raf kinase, have not been
delineated (Post and Brown, 1996; van Biesenet al., 1996).
Seven transmembrane GPCRs comprise the largest
known family of cell surface receptors and they mediate
cellular responses by a diverse array of ligands, including
peptide and glycopeptide hormones, neurotransmitters,
phospholipids, odorants, and even photons (van Biesen
et al., 1996). Activation of GPCRs catalyzes exchange of
GTP for GDP within the heterotrimeric G-protein complex
releasing activated Gα–GTP and Gβγ subunits, each of
which has regulatory functions (Dhanasekaranet al.,
1995). As with PKC activation alone, the mechanism of
GPCR ERK activation varies and has not been fully
elucidated. In studying GPCRs in rat liver epithelial cells,
we demonstrated angiotensin II (Ang II)-, vasopressin-
and α1 agonist-stimulated tyrosine phosphorylation
(Huckleet al., 1990; Huckle and Earp, 1992). We purified
and identified the calcium-dependent tyrosine kinase
(CADTK) (Earp et al., 1995; Yuet al., 1996) which was
identified concurrently by others using different molecular
approaches and has been named Pyk2 (Levet al., 1995),
RAFTK (Avraham et al., 1995), CAKβ (Sasakiet al.,
1995) and FAK2 (Herzoget al., 1996). CADTK activation
appears to regulate the c-Jun N-terminal kinase pathway
(Zohn et al., 1995; Tokiwaet al., 1996; Yuet al., 1996;
Li et al., 1997; Liu et al., 1997) as well as cytoskeleton
protein tyrosine phosphorylation, e.g. paxillin and p130CAS
PKC in Ang II-dependent EGF receptor transactivation
(Astier et al., 1997; Li and Earp, 1997; Rajaet al., 1997).
However, in GN4 cells, CADTK does not activate the
ERK pathway, although it does in PC12 cells (Lev
et al., 1995).
The present study demonstrates that Ang II activates
ERK in GN4 cells through two pathways. In control cells,
Ang II stimulated ERK through what appears to be a
PKC-dependent, Ras/Raf-independent pathway. However,
when the PKC-dependent pathway was abolished, Ang II
stimulated a new set of tyrosine phosphoproteins (e.g.
Cbl) and still activated ERK to almost the same extent.
Thus, PKC depletion uncovered an alternative Ras/Raf-
dependent mechanism virtually as efficacious as the
original. Several recent reports demonstrated cell-type
specific, GPCR-dependent EGF receptor activation, e.g.
endothelin stimulates EGF receptor and HER2/neu tyro-
sine phosphorylation in Rat-1 fibroblast cells (Daubet al.,
1996) and the m1 muscarinic acetylcholine receptor
(mAChR) transactivates the EGF receptor in the m1
mAChR transfected human 293 cells (Tsaiet al., 1997).
In this report, we demonstrate that Ang II and vasopressin
stimulate EGF receptor tyrosine phosphorylation, but only
when PKC is inhibited or depleted. PKC activation has
long been known to decrease the affinity of the receptor
for EGF and to block EGF-dependent signal transduction.
The physiological reason for this PKC-dependent negative
regulation has never been apparent, nor is the mechanism
firmly established (Morrisonet al., 1996). Our current
data suggest another important function for this negative
regulation—prevention of a proliferative EGF receptor
signal by ubiquitously expressed GPCRs. Agonists for
these receptors are used for so many aspects of cell
signaling that a linked proliferative signal with each
engagement would be problematic. An intriguing question
remains: ‘When is the GPCR–EGF receptor interaction
physiologically relevant?’
Results
Expression of dominant interfering Ras(N17)
inhibits EGF- but not TPA-dependent ERK
activation
Previously, we showed that Ang II and thapsigargin
stimulated JNK in a calcium-dependent, PKC-independent
manner (Zohnet al., 1995). JNK activation was correlated
with CADTK stimulation (Yu et al., 1996). In contrast,
in GN4 cells the calcium/CADTK-dependent pathway did
not result in ERK activation (Yuet al., 1996), nor did it
increase c-Fos expression (Liet al., 1997). Thus, we
assumed that Ang II stimulated both ERK and AP-1
nuclear activity via a PKC-dependent pathway, and were
surprised when Ang II retained the ability to increase
ERK and AP-1 activity in cells depleted of PKC (Zohn
et al., 1995). To examine the role of Ras in this Ang II
action, we established two clonal GN4 cell lines (S-5 and
S-19), which expressed a dominant interfering form of
the Ha-Ras protein, Ras(N17), under the control of an
inducible promoter, the mouse mammary tumor virus
(MMTV) long terminal repeat (Cai and Cooper, 1995).
Treatment of stably transfected cells with dexamethasone
(DEX) significantly increased Ras(N17) expression in
these cells, whereas treatment with vehicle dimethysulf-
oxide (DMSO) did not (data not shown).
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Fig. 1. EGF-dependent ERK activation is Ras-dependent. Rat liver
epithelial cells (GN4) and Ras(N17) transfected GN4 cells (S-5, S-19)
were pretreated with or without DEX (1µM, 24 h) followed by
stimulation with EGF (100 ng/ml, 5 min). Cell lysates were prepared
and subjected to 15% SDS–PAGE followed either by (A) anti-ERK
immunoblotting for ERK gel mobility shift or (B) by immuno-
precipitating with anti-ERK antibody (C-l6) for ERK immune complex
kinase activity assays with MBP as a substrate followed by gel
electrophoresis and autoradiography to detect32P-MBP.
The consequence of Ras(N17) expression was tested by
examining EGF-dependent ERK activation. As expected,
EGF (100 ng/ml, 5 min) strongly activated ERK in control
GN4 cells transfected with the vector alone, in either the
presence or absence of DEX pretreatment. However,
induction of Ras(N17) blocked EGF-dependent ERK
activation (Figure 1A and B), confirming that induction
of Ras(N17) in the S-5 and S-19 cell lines was sufficient
to interfere with endogenous Ras signaling.
To define the TPA-dependent pathway in GN4 cells,
ERK activation was again studied in the Ras(N17)-
inducible cell lines. TPA activated ERK similarly in GN4
cells, with or without induction of Ras(N17) (Figure 2A
and B). However, when PKC was depleted by chronic
exposure of GN4 cells to TPA (5µM, 18 h), the TPA-
dependent activation of ERK was nearly abolished (Figure
2A and B). This result suggests that PKC activates ERK
through primarily a Ras-independent pathway in GN4
cells. While expression of Ras(N17) does not block all
potential mechanisms by which Ras can be activated (i.e.
suppression of GAP activity), this type of experiment
generally delineates Ras-dependent and -independent path-
ways. To investigate this further, we studied Ras-GDP to
-GTP exchange and Raf activation.
Ang II activates ERK through two independent
pathways
Like TPA, Ang II activated ERK in control cells whether
or not Ras(N17) was induced (Figure 2C and D), sug-
gesting that Ang II activates ERK through a Ras-inde-
pendent, PKC-dependent pathway. However, in contrast
with TPA, PKC-depletion did not appreciably inhibit the
activation of ERK by Ang II (Figure 2C and D). Intri-
guingly, Ras(N17) induction in PKC-depleted cells
inhibited Ang II-dependent ERK activation (Figure 2C
and D). These data suggest that Ang II is capable of
stimulating ERK by two pathways: in naive cells, Ang II
activated ERK via a PKC-dependent, Ras-independent
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Fig. 2. Assessment of Ras and PKC-dependence of TPA and Ang II-
dependent ERK activation. GN4 cells and Ras(N17) transfected GN4
cells (S-5, S-19) were pretreated with or without DEX (1µM, 24 h)
and TPA (5µM, 18 h) or both, followed by acute treatment with TPA
(100 nM, 5 min) or Ang II (1µM, 5 min). Cell lysates were subjected
to anti-ERK immunoblotting for gel mobility shift (A andC) or
assessed for ERK activity by immune complex kinase activity assay
(B andD) as described in Materials and methods. TPA-dependent
ERK activation was not altered by DEX induction of Ras(N17) but
was abolished by PKC depletion (A and B). Neither induction of
Ras(N17) nor depletion of PKC alone blocked ERK activation by Ang
II. However, the combination of both resulted in the inhibition of Ang
II-dependent ERK activation, i.e. in PKC-depleted cells the pathway
became Ras-dependent (C and D).
pathway; while in PKC-depleted cells, Ang II stimulated
ERK via a Ras-dependent pathway.
The two pathways were further confirmed by measuring
Ras–GTP level and Raf kinase activity in naive or PKC-
depleted cells. Ang II and TPA treatment produced only
minimal increases in Ras–GTP level in naive GN4 cells
(Figure 3A). In contrast, Ang II significantly stimulated
Ras–GTP level in PKC-depleted GN4 cells. While Ang
II and TPA activated Raf kinase activity by a small
increment (~60–70%) in naive GN4 cells, Ang II stimu-
lated Raf kinase activity by an additional 2-fold in PKC-
depleted GN4 cells (Figure 3B). The small effect of TPA
was abolished by PKC depletion (Figure 3B) and the
stimulation of Raf by Ang II in PKC-depleted cells was
completely abrogated by induction of Ras(N17) (data not
shown). The major increase in Ang II-dependent Ras–
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Fig. 3. Ang II increased Ras–GTP level and Raf kinase activity in
PKC-depleted GN4 cells. GN4 cells pretreated with or without TPA
(5 µM, 18 h) were stimulated by Ang II (1µM), TPA (100 nM) and
EGF (100 ng/ml) for the indicated time. Cell lysates were prepared
and immunoprecipitated with (A) anti-Ha Ras or (B) anti-c-Raf
antibodies. Ras–GTP level and c-Raf immune complex-kinase assays
were then performed as described in Materials and methods. Ang II
significantly activated Ras and Raf in PKC-depleted cells but TPA and
Ang II-dependent effects in naive GN4 cells are minimal.
GTP level and Raf kinase activity in PKC-depleted cells
confirms use of an alternative pathway. PKC-dependent
ERK activation pathway predominates in naive rat liver
epithelial cells while PKC depletion unmasks signaling
through a Ras- and Raf-dependent pathway. Surprisingly,
the two pathways yield nearly equivalent ERK (Figure 2)
and MEK activation in these cells (data not shown). While
we cannot rule out that a slight TPA-dependent increase
in Ras–GTP level due to inhibition of GAP activity is
involved in ERK activation, these data are most consistent
with PKC acting via a Ras-independent pathway in these
cell types.
Ang II treatment increases Shc and Cbl tyrosine
phosphorylation
Shc is tyrosine phosphorylated in response to a number
of stimuli and is thought to be a key intermediate in
PKC in Ang II-dependent EGF receptor transactivation
Fig. 4. Ang II increased Shc and Cbl tyrosine phosphorylation in
PKC-depleted GN4 cells. GN4 cells with or without TPA pretreatment
(5 µM, 18 h) were stimulated with EGF (100 ng/ml), Ang II (1µM)
or thapsigargin (2µM) for 2.5 min. Cell lysates were prepared and
immunoprecipitated with anti-Shc or anti-Cbl antibodies and the
precipitates were subjected to SDS–PAGE. Immunoblot was probed
with anti-Tyr(P) antibody (A andC), stripped, and reprobed with
anti-Shc antibody (B) or anti-Cbl antibody (D).
growth factor receptor signaling to the Ras/Raf pathway
(Pawson, 1995). As expected, EGF dramatically increased
Shc tyrosine phosphorylation in GN4 cells, whereas Ang
II did not (Figure 4A and B). However, in PKC-depleted
cells Ang II slightly enhanced Shc tyrosine phosphoryl-
ation, although this effect was variable. In contrast, thapsi-
gargin treatment, which stimulates CADTK, did not
increase Shc tyrosine phosphorylation in either naive or
PKC-depleted GN4 cells. Thus, CADTK is not the tyrosine
kinase that phosphorylates Shc in Ang II-treated GN4 cells.
To investigate alternatives, we examined the tyrosine
phosphorylation of Cbl, an adaptor protein which is a
major EGF receptor substrate. The role of Cbl in Ras
activation is somewhat controversial, but it has been
implicated in some cells (Fukazawaet al., 1995; Buday
et al., 1996; Panchamoorthyet al., 1996; Reedquistet al.,
1996; Ribonet al., 1996). Ang II treatment had little
effect in naive GN4 cells, but consistently increased Cbl
tyrosine phosphorylation in PKC-depleted cells (Figure
4C and D). Thapsigargin did not increase Cbl tyrosine
phosphorylation in either naive or PKC-depleted GN4
cells. These data suggest that in PKC-depleted GN4 cells,
an additional tyrosine kinase is now activated, stimulating
Shc and Cbl tyrosine phosphorylation.
One obvious question is whether the effect of overnight
TPA treatment is simply depletion (inactivation) of PKC,
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Fig. 5. Acute PKC inhibition with GF109203X mimics PKC
depletion; both increased Ang II-dependent Cbl tyrosine
phosphorylation. GN4 cells with or without various doses of
GF109203X (15 min pretreatment) were stimulated with Ang II
(1 µM, 90 s). Cell lysates were prepared and immunoprecipitated with
anti-Cbl antibody. The immunoblot was probed with anti-Tyr(P)
antibody (A), stripped, and reprobed with anti-Cbl antibody (B). At
higher doses, GF109203X increased Ang II-stimulated Cbl tyrosine
phosphorylation to an extent similar to that of PKC depletion caused
by TPA (5 µM, 18 h) (lane 4).
or whether prolonged TPA alters gene expression leading
to the Ang II-dependent tyrosine phosphorylation pathway.
To address this, we repeated the experiments on cells in
which PKC activity has been acutely inhibited by treatment
with GF109203X. Incubation with GF109203X produced
a dose- and time-dependent (Figure 5; data not shown)
increase in Ang II-dependent Cbl tyrosine phosphorylation,
suggesting that it was a lack of PKC activation that
allowed Ang II-dependent Cbl tyrosine phosphorylation.
Ang II-dependent tyrosine kinase activation
To determine whether PKC-depletion affected the ability
of Ang II to stimulate specific tyrosine kinases, we
immunoprecipitated tyrosine kinases from control and
PKC-depleted GN4 cells and studied either their tyrosine
autophosphorylation or their tyrosine kinase activity. The
tyrosine autophosphorylation of p125FAK was unaffected
by PKC depletion, while Ang II-dependent CADTK tyro-
sine phosphorylation was slightly decreased (Figure 6).
Src or Src-family tyrosine kinases have been reported to
stimulate Shc and/or Cbl tyrosine phosphorylation in
response to GPCRs in some cell lines, and increased Src
family kinase activity has often been correlated with ERK
activation (Fukazawaet al., 1995; Dikic et al., 1996;
Sadoshima and Izumo, 1996). However, immunoprecipit-
ation of Src and Fyn from control or PKC-depleted cells
followed by phosphotyrosine immunoblotting failed to
detect any reproducible difference (Figure 6). Next,
immune complex tyrosine kinase assays were performed
using Src and Fyn immunoprecipitates from control and
PKC-depleted cells, both with and without Ang II stimul-
ation. Using poly(Glu80Tyr20) as a substrate, Src and Fyn
tyrosine kinase activity was slightly increased (,1.3-fold)
in response to Ang II treatment; however, the increases
in Src and Fyn kinase activity were similar in both naive
and PKC-depleted GN4 cells (data not shown). Thus, Src
and Fyn are probably not the key intermediates in Ang
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Fig. 6. PKC-depletion did not increase p125FAK, CADTK, Src or Fyn
tyrosine phosphorylation in response to Ang II treatment. GN4 cells
with or without TPA pretreatment (5µM, 18 h) were stimulated with
Ang II (1 µM, 90 s). Cell lysates were prepared, immunoprecipitated
with anti-Cbl, p125FAK, CADTK, Src and Fyn, respectively, and
immunoblotted with anti-Tyr(P) antibody. (A) and (B) show that PKC-
depletion did not appreciably alter the extent of p125FAK, CADTK,
Src and Fyn tyrosine phosphorylation in response to Ang II.
II-dependent Cbl tyrosine phosphorylation or ERK activ-
ation in PKC-depleted GN4 cells.
Ang II increased EGF receptor tyrosine
phosphorylation resulting in ERK activation in
PKC-depleted cells
Shc and Cbl are both EGF receptor substrates and therefore
we examined Ang II-dependent EGF receptor tyrosine
phosphorylation. Ang II treatment had little effect on EGF
receptor tyrosine phosphorylation in naive GN4 cells but
produced a time-dependent increase in EGF receptor
tyrosine phosphorylation in PKC-depleted GN4 cells
(Figure 7A and B). The same effect was observed when
cells were treated with [Arg8] vasopressin (data not shown),
suggesting that multiple Gq protein-coupled receptors
transactivate the EGF receptor in PKC-depleted GN4 cells.
Both Ang II-dependent EGF receptor and Cbl tyrosine
phosphorylation lagged 15–30 s behind that of EGF, as
would be expected from a less direct activation mechanism
(Figure 7A and C). The extent of EGF receptor tyrosine
phosphorylation is substantially less with Ang II than with
EGF, but it should be noted that GN4 cells express
~300 000 EGF receptors per cell (Tsaoet al., 1986);
activation of 5–10% of this receptor number is probably
sufficient to produce a biological effect (Figure 10).
To investigate further whether Ang II stimulation
increased the EGF receptor tyrosine phosphorylation
directly or whether a secondary kinase resulted in EGF
receptor tyrosine phosphorylation, we incubated cells
with several EGF receptor-specific inhibitors, such as
PD153035 (Figure 8) and PD 158780 (data not shown)
(Fry et al., 1994). These compounds completely blocked
EGF- and Ang II-stimulated Cbl tyrosine phosphorylation
in PKC-depleted GN4 cells (Figure 8A). Both inhibitors,
PD153035 (Figure 8C) and PD 158780 (data not shown),
blocked EGF and Ang II-dependent EGF receptor tyrosine
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Fig. 7. The time course of Ang II- and EGF-stimulated EGF receptor
and Cbl tyrosine phosphorylation in PKC-depleted GN4 cells. PKC-
depleted (5µM, 18 h, TPA) GN4 cells were treated with Ang II
(1 µM) or EGF (100 ng/ml) for the indicated time. Cell lysates were
prepared and immunoprecipitated with anti-EGF receptor (1382) (A
andB) or anti-Cbl (C andD). The immunoblot was probed with anti-
Tyr(P) (A and C), then stripped and reprobed with anti-EGF receptor
(#22) (B) or anti-Cbl antibody (D). EGF dramatically increased Cbl
tyrosine phosphorylation in as little as 15 s; Ang II-dependent Cbl
tyrosine phosphorylation was delayed by 15–30 s with the peak at
~45–90 s. The exposure time for the EGF treated EGF receptor anti-
Tyr(P) blot was shorter than that of the Ang II-dependent EGF
receptor phosphorylation to allow better visualization of the time
courses.
phosphorylation in PKC-depleted GN4 cells. These experi-
ments using selective EGF receptor tyrosine kinase
inhibitors suggest that GPCRs stimulate Cbl tyrosine
phosphorylation via an EGF receptor mediated mechanism
in PKC-depleted rat liver epithelial cells. (Since Ang II-
stimulated EGF receptor tyrosine phosphorylation took
only 15–30 s, it is unlikely that release of an autocrine
ligand is involved in this process.)
Furthermore, we examined whether an Ang II EGF
receptor pathway might explain the original biological
observation of Ang II- and Ras/Raf-dependent ERK activ-
ation in PKC-depleted cells. Ang II and EGF increased
ERK gel mobility shift in naive and PKC-depleted GN4
cells (Figure 9). PD153035 pretreatment completely
blocked both the Ang II- and EGF-dependent effects in
PKC-depleted cells. As expected, the selective EGF recep-
tor tyrosine kinase inhibitor blocked the effect of EGF in
naive cells but did not block the Ang II-dependent ERK
activation (Figure 9, right three lanes), confirming the
EGF receptor-independent nature of Ang II action in
naive cells.
Finally, having established that Ang II-dependent EGF
receptor transactivation was necessary for ERK activation
in PKC depleted cells (Figure 9), we attempted to examine
whether this transactivation was sufficient to activate ERK.
PKC in Ang II-dependent EGF receptor transactivation
Fig. 8. PD153035 abolished Ang II-dependent EGF receptor and Cbl
tyrosine phosphorylation in PKC-depleted cells. GN4 cells with or
without TPA pretreatment (5µM, 18 h) were treated with PD153035
(1 µM, 2 h) then stimulated with EGF (100 ng/ml, 90 s) or Ang II
(1 µM, 90 s), respectively. Cell lysates were immunoprecipitated with
anti-Cbl antibody or anti-EGF receptor (1382) antibody, then subjected
to SDS–PAGE and immunoblotted with anti-Tyr(P) antibody.
Pretreatment of PD153035 completely inhibited EGF and Ang II-
mediated Cbl (A andB) and EGF receptor (C andD) tyrosine
phosphorylation. The same results were obtained with PD 158780
(data not shown).
Fig. 9. PD153035 abolished Ang II-dependent ERK activation in
PKC-depleted but not in control cells. GN4 cells with or without TPA
(5 µM, 18 h) and PD153035 (1µM, 2 h) pretreatment were stimulated
with EGF (100 ng/ml, 90 s) or Ang II (1µM, 90 s). Cell lysates were
prepared and subjected to SDS–PAGE, then immunoblotted with anti-
ERK antibody. EGF and Ang II increased ERK gel mobility shift in
both naive and PKC-depleted GN4 cells. However, Ang II-stimulated
ERK gel shift was only inhibited with PD153035 treatment in PKC-
depleted cells; the Ang II effect in naive cells was not blocked by
PD15035 (outside right lane). EGF-dependent ERK activation was
abolished by PD153035 under all conditions.
Ang II (1 µM) treatment induced EGF receptor tyrosine
phosphorylation that was similar to that produced by
1 ng/ml EGF (Figure 10A). Ang II (1µM) and EGF
(1 ng/ml) treatment induced a similar amount of Cbl
tyrosine phosphorylation in these cells (Figure 10C). Ang
II and 1–2 ng/ml EGF treatment also resulted in similar
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Fig. 10. Ang II-induced EGF receptor transactivation was sufficient to
activate downstream signaling. PKC-depleted GN4 cells were treated
with Ang II (1 µM) and EGF as indicated and concentrated for 90 s,
respectively. Cell lysates were immunoprecipitated with anti-EGF
receptor and anti-Cbl antibodies, respectively, and then subjected to
SDS–PAGE and immunoblotted with anti-Tyr(P) antibody (A and C).
Immunoblots were stripped and reprobed with (B) anti-rat EGF
receptor or (D) anti-Cbl. Cell lysates were also subjected to SDS–
PAGE and immunoblotted with anti-ERK antibody (E). OneµM Ang
II treatment stimulated EGF receptor (A) and Cbl (C) tyrosine
phosphorylation to the same extent as 1 ng/ml EGF. ERK activation
by Ang II was equivalent to 1–2 ng/ml EGF (E).
amounts of ERK activation (Figure 10E), suggesting
that Ang II-induced EGF receptor transactivation was
necessary and sufficient to activate downstream signaling.
Discussion
While it is widely accepted that GPCRs regulate ERKs
(Post and Brown, 1996), the pathways used are not always
defined and may vary between cell types or even receptor
subtypes (Post and Brown, 1996; van Biesenet al., 1996).
Our studies demonstrate the following in rat liver epithelial
cells: first, Ang II can stimulate ERK via two independent
pathways, a putative Ras/Raf-independent, PKC-depend-
ent pathway in naive GN4 cells and a Ras/Raf-dependent
pathway observed when PKC activation is prevented.
Secondly, the latter pathway may involve adaptor protein
tyrosine phosphorylation as exemplified by Cbl and Shc
(Figure 4). Tyrosine phosphorylation of these proteins is
only seen in the absence of PKC activity. Thirdly, the
Ang II, Ras-dependent pathway in PKC-depleted cells
appears to involve the EGF receptor. Ang II stimulated
EGF receptor and Cbl tyrosine phosphorylation in PKC-
depleted GN4 cells (Figure 7); both these effects were
abolished by selective EGF receptor tyrosine kinase inhib-
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itors as was Ang II-dependent, Ras/Raf-dependent ERK
activation (Figures 8 and 9). Finally, Ang II-dependent
transactivation of the EGF receptor appeared to be neces-
sary and sufficient to activate downstream signaling, such
as ERK (Figure 10).
The mechanism controlling the switch between these
two independent ERK activation pathways is not yet
known, but inhibition of PKC is a key factor. It has long
been known that PKC can phosphorylate the EGF receptor
(Cochetet al., 1984; Iwashita and Fox, 1984) on threonine
residue 654 (Hunteret al., 1984; Davis and Czech, 1985)
and that acute TPA treatment inhibits EGF receptor
signaling function by several mechanisms. EGF binding
to surface EGF receptors is reduced either by decreasing
receptor affinity for EGF (~10-fold) or by triggering
ligand-independent internalization of the receptor
(Beguinotet al., 1985; McCune and Earp, 1989). Receptor
internalization into intracellular vesicles capable of
recycling occurs in selected epithelial cells but not in
most fibroblasts. TPA also downregulates EGF receptor
signaling by inhibiting EGF-dependent EGF receptor tyro-
sine kinase activity (Cochett al., 1984; Friedmannet al.,
1984; McCune and Earp, 1989). The mechanism by which
TPA acts remains controversial. Initial studies suggested
the PKC-dependent phosphorylation of Thr 654 in the
juxtamembrane region was sufficient to explain down-
regulation. More recent data suggest that in some cells,
mutated EGF receptor (Thr 654 to Ala 654) can also
be inhibited by TPA treatment, indicating an additional
mechanism in those cells (Morrisonet al., 1996). The
mechanism proposed for the Thr 654-independent inhibi-
tion involves MEK/ERK activation by TPA. We have not
yet determined whether Thr 654 phosphorylation is a
key event preventing Ang II-dependent EGF receptor
transactivation in GN4 cells; however, MEK/ERK activ-
ation cannot be the inhibitory mechanism because both
are fully activated in PKC-depleted cells (Figure 2; data
not shown). Interestingly, and in contrast with our findings
in rat liver epithelial cells, m1 mAChR-induced EGF
receptor transactivation is a PKC-dependent process in
human 293 cells (Tsaiet al., 1997). These latter data
suggest that the mechanism of GPCR-induced EGF recep-
tor transactivation varies in different tissues and cells.
One possible explanation that must be explored is the
differential role of the multiple PKC isoforms.
Ang II-dependent adaptor protein tyrosine phosphoryl-
ation (e.g. Cbl and Shc) in PKC-depleted GN4 cells may
link the Ang II EGF receptor signal to the ERK pathway.
While less is known about Cbl, first identified as the
cellular homolog of the murine retrovirus Cas-NS-1 trans-
forming gene (v-cbl) (Langdon, 1995), this EGF receptor
substrate has been linked to the Ras pathway in some cells
(Fukazawaet al., 1995; Budayet al., 1996; Panchamoorthy
et al., 1996; Reedquistet al., 1996; Ribonet al., 1996).
By sequence analysis, Cbl contains many protein–protein
interaction domains including an SH3, a leucine zipper
domain, a Cys3–His–Cys3 ring finger and a recently
identified phosphotyrosine-binding domain that interacts
with cellular tyrosine kinases and potentiates their signal-
ing (Bonita et al., 1997). Cbl is rapidly tyrosine-phos-
phorylated in response to EGF receptor activation as well
as by non-receptor tyrosine kinases on T and B cells
(Langdon, 1995); Cbl may stimulate Ras through Crk
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(Buday et al., 1996; Reedquistet al., 1996) or Grb2
adaptor proteins (Fukazawaet al., 1995; Meisneret al.,
1995; Budayet al., 1996; Panchamoorthyet al., 1996).
With regard to the role of Shc, Ang II activates Ras
by increasing Shc tyrosine phosphorylation in cardiac
myocytes (Sadoshima and Izumo, 1996) and thrombin
stimulates Shc tyrosine phosphorylation via a Gq-mediated
pathway in growth-responsive CCL39 fibroblasts
(Pumiglia et al., 1995). In PC12, bradykinin activates
Pyk2/CADTK, stimulates Shc tyrosine phosphorylation
and results in Pyk2–Grb2 association (Levt al., 1995).
This is not the case in GN4 cells; neither thapsigargin nor
calcium ionophore, which activate CADTK, increased Cbl
or Shc tyrosine phosphorylation or ERK activity.
In some cells, Src and Src-family tyrosine kinases may
be required for GPCR/ERK activation. Stimulation of
ERK by Gq-coupled m1 mAChRs is blocked in avian B
lymphoma cell lines deficient in the Src-family tyrosine
kinase, Lyn (Wanet al., 1996). The GPCR-Pyk2/CADTK
pathway to ERK in PC12 cells mentioned above is thought
to involve a Pyk2 and Src complex. Interestingly, Csk
activation, which inhibits ERK activation in PC12 cells
(Dikic et al., 1996), is required for Gq protein-coupled
receptor activation of ERK in DT40 cells (Wanet al.,
1997). How GPCR activates Src or Src family tyrosine
kinases is still not clear; however, expression Csk or
dominant-negative Src kinase mutants inhibit Gi protein-
coupled receptor (and Gβ1γ2 subunits-mediated) phos-
phorylation of both EGF receptor and Shc (Luttrellt al.,
1997). In GN4 cells, however, the Ang II-dependent
increase in Src and Fyn tyrosine kinase activity was
minimal and was not changed with PKC-depletion, sug-
gesting that Src and Fyn play only a minor role, if
any, in Ang II-dependent ERK activation in rat liver
epithelial cells.
Stimulation of EGF receptor tyrosine phosphorylation
by agents other than EGF family member ligands has
been reported by several groups. Calcium ionophore
produces this effect in cells of neural origin (Rosen and
Greenberg, 1996; Zwicket al., 1997), but thapsigargin
does not stimulate EGF receptor phosphorylation in GN4
cells and, thus, calcium is not the intermediary in GN4
cells. As mentioned above, a pathway of EGF receptor
phosphorylation from Gi-linked receptors involving Src
family kinases has been suggested by overexpression of
Gi and βα in Cos-7 cells (Luttrellet al., 1997). Perhaps
closest to our observation is the report by Ullrich and
colleagues that endothelin-1 activates the EGF receptor
as well as rat p185neu in Rat-1 fibroblast cell lines (Daub
et al., 1996). However, this was observed in Rat-1 cells
without any attempt to modify PKC activity. Thus, either
endothelin does not activate the PKC inhibitory pathway,
or PKC is not a negative regulator in all cell types. A
PKC isoform present in rat liver epithelial, and not in
Rat-1 fibroblast, cell lines may be responsible for the
GPCR→EGF receptor pathway inhibition; alternatively,
endothelin may use a different positive signal between its
receptor and the EGF receptor. The presence of a GPCR
pathway to EGF receptor and ERK activation has implic-
ations for the manner in which this ubiquitous class of
receptors regulates to proliferation and differentiation
systems. It is not surprising that a mechanism prevents
multiple GPCRs from committing the cell to a major
PKC in Ang II-dependent EGF receptor transactivation
energy-expending process such as cell growth. Thus, the
masking of this growth stimulating pathway by PKC
makes physiological sense. The intriguing question (in
addition to the mechanism by which this occurs) is why
a G protein/EGF receptor pathway exists and under what
physiological conditions it is operable.
Materials and methods
Materials
Human recombinant EGF was purchased from Gibco-BRL. Ang II was
purchased from Sigma and prepared in 50 mM acetic acid as stock
solution. Phorbol 12-myristate 13-acetate (TPA), thapsigargin and DEX
were purchased from Sigma, GF 109203X from Calbiochem, prepared
as stock solutions in DMSO. PD153035 and PD158780 were kindly
provided by Dr David W.Fry (Parke-Davis). Anti-CADTK polyclonal
antibodies were as described previously (Yuet al., 1996). Anti-p125FAK
monoclonal antibody was kindly provided by Dr Tom Parsons (University
of Virginia). Anti-Src monoclonal antibody (327) was generously pro-
vided by Dr Joan Brugge (Harvard University). Anti-Fyn polyclonal
antibody was kindly provided by Dr Andre Veillette (McGill University).
Anti-Tyr(P) monoclonal antibody, PT66, was purchased from Sigma.
Anti-ERKs polyclonal antibodies (C-16 and K-23), anti-HaRas (259)
AC, anti-Raf-1 polyclonal antibody (C-12) and anti-Cbl polyclonal
antibody (C-15) were purchased from Santa Cruz Biotechnology. Anti-
Shc polyclonal and anti-Grb2 monoclonal antibodies were purchased
from Transduction Laboratory.
Cell culture
Rat liver epithelial cells, GN4, were grown in Richter’s improved
minimal essential medium as described previously (Earpet al., 1995).
Ras(N17) stable integrated GN4 cell lines were established by transfecting
GN4 with the pMMTV-Ras(N17) plasmid by lipofectAMINE according
to the manufacturer’s instructions (Gibco-BRL). Transfected GN4 cells
were selected by incubating cells with G418 containing medium
(400 µg/ml). Colonies were picked using cloning rings.
Cell lysate preparation
Cell lysate preparation was performed essentially as described previously
(Earpet al., 1995). Briefly, cells treated with agonists were scraped into
ice-cold cell lysis buffer [150 mM NaCl, 20 mM Tris pH 7.5, 1% Triton
X-100, 5 mM EDTA, 50 mM NaF and 10% (v/v) glycerol] with freshly
added 1 mM Na3VO4, 20 µg/ml phenylmethylsulfonylfluoride (PMSF),
10 µg/ml leupeptin and 100 kallikrein inhibitor units of aproptinin per
ml. Cell lysates were clarified by centrifugation and their protein content
was determined by Coomassie protein assay reagent (Pierce).
Immunoprecipitation and immunoblotting
In a typical experiment, ~750µg of cell lysate was immunoprecipitated
by incubation with the antibody for 2 h at 4°C. Twentyµl of protein A
agarose beads were then added for an additional 1 h. Immune complexes
were collected by centrifugation, washed three times with lysis buffer
and resuspended in SDS–PAGE sample buffer. Samples were subjected
to SDS–PAGE, transferred to Immobilon (Millipore) and incubated with
the selected antibody. Immunoblots were developed with ECL according
to the manufacturer’s instructions (Amersham). Immunoblots were
stripped in the buffer (62.5 mM Tris pH 6.8, 2% SDS, 100 mM
β-mercaptoethanol) at 50°C for 30 min and reprobed with another
antibody.
ERKs activation assays
Activation of ERKs was determined as described previously (Yuet al.,
1996). Briefly, 15µg of cell lysates were resolved on 15% low bis SDS–
PAGE. Proteins were then transferred to nitrocellulose membranes for
analysis by immunoblotting with the anti-ERKs antibody (K-23). The
immunoblot was developed by ECL according to the manufacturer’s
procedure (Amersham). ERKs activity were determined by immunopre-
cipitated ERKs with anti-ERKs antibody (C-16) from cell lysate. Immune
complexes were then washed three times with lysis buffer and once with
kinase buffer. Immune complexes kinase assay was performed using
[γ-32P]ATP and myelin basic protein (MBP) as substrates. Reaction
mixtures were then subjected to 12% SDS–PAGE, followed by Coomassie
Blue staining and autoradiography.
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Ras–GTP level assay
Ras activation was determined as described previously (Downwardet l.,
1991) with some modification. Briefly, naive or PKC-depleted GN4 cells
(100 mm dish) were incubated with 1 mCi32P-orthophosphate for 2 h
before agonists were added. After washing, the cells were scraped into
1 ml of Ras lysis buffer (50 mM HEPES pH 7.4, 1% Triton X-100,
5 mM MgCl2, 1 mg/ml BSA, 10 mM benzamidine HCl, 0.5% sodium
deoxycholate, 0.05% SDS, 1 mM PMSF, 10µM leupeptin and 10µM
pepstatin A). Supernates of cell lysates were incubated with anti-Ha Ras
(259) AC for 2 h at 4°C. The beads were collected by brief microfugation
and washed five times with washing buffer (50 mM HEPES pH 7.4,
0.5 M NaCl, 5 mM MgCl2, 0.1% Triton and 0.005% SDS). The bound
nucleotides were eluted by adding 30µl of freshly made elution buffer
(2 mM EDTA, 2 mM dithiothreitol, 0.2% SDS, 0.5 mM GTP, 0.5 mM
GDP) and incubating at 68°C for 20 min. The supernates were spotted
on polyethyleneimine–cellulose TLC plates (Sigma). The plates were
developed in 0.8 M HCl/1.2 M ammoniumformate and analyzed by
phosphoimager.
Raf-1 activity assay
One mg of cell lysates were used to immunoprecipitate c-Raf by anti-
c-Raf antibody (C-12) and protein A agarose beads. The immune
complexes were washed twice with lysis buffer and twice with ice-cold
phosphate-buffered saline (PBS). The Raf-1 immune complex kinase
activity was measured through a coupled enzyme assay combining MEK,
ERK2 and MBP. Briefly, immune complexes were incubated with 0.5µg
of recombinant MEK and 10µl of a cold ATP mixture (30 mM
β-glycerophosphate, 60 mM HEPES pH 7.3, 4 mM EGTA, 1.5 mM
dithiothreitol, 0.45 mM Na3VO4, 30 mM MgCl2, 0.3 mM ATP and
0.3 mg/ml BSA) for 10 min at 30°C. The 1.25µg of ERK2 was added
and incubated for an additional 10 min. Finally, 20µl of a hot ATP
mixture (2µCi of [γ-32P]ATP, 10µg of MBP, 30 mMβ-glycerophosphate,
60 mM HEPES pH 7.3, 4 mM EGTA, 1.5 mM dithiothreitol, 0.45 mM
Na3VO4, 30 mM MgCl2 and 6µg of BSA) was added and incubated
for 10 min at 30°C before stopping the reaction by the addition of 20µl
of EDTA. The reaction mixtures were then centrifuged at 12 000g for
1 min. Forty µl of each supernatant was spotted onto P81 paper. The
papers were then washed five times (5–10 min) with 75 mM phosphoric
acid, soaked briefly with 100% ethanol and air dried prior to performing
liquid scintillation counting.
Tyrosine kinase activity assay
The immune complex tyrosine kinase assay was performed as reported
previously (Huckle and Earp, 1992). Briefly, immune complex suspen-
sions were preincubated for 5 min at 4°C with 160µg of the synthetic
tyrosine kinase substrate poly(Glu80Tyr20) (Sigma) or the control sub-
strate poly(Glu). Reactions (80µl total reaction volume) were initiated
by adding of 5µCi [γ-32P]ATP. After 15 min at 25°C, 50µl of the
reaction mixture was spotted on P81 Whatman paper. The papers were
washed once with 10 mM Na-pyrophosphate in 10% trichloroacetic acid
and twice with 5% trichloroacetic acid, air-dried and assayed by liquid
scintillation counting.
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